The race to market: Strategies for rapid therapeutic screening in immune cells

Therapeutic screening in immune cells allows drug developers to identify and test drug candidates that can modulate immune cell function. This assessment is critical for developing effective treatments for various diseases, including cancer and autoimmune disorders. Equally important is that it allows immune safety tests for the drug candidates before clinical trials.

By applying semi-automated methodologies to therapeutic screening in immune cells you can test large numbers of compounds for their ability to modulate immune cell function in high throughput. By incorporating automation in immune cell-based assays, Revvity has developed a platform that increases data robustness and offers multiplex endpoint readouts with additional customizable capabilities that utilize gene editing CRISPR technologies.

In this webinar, Dr. Yuki Kataoka, a scientist at Taiho Pharmaceutical Co, and Dr. Isabelle Nett, a team leader in the cell-based screening department at Revvity, will discuss their experience in assessing therapeutic candidates' immunogenicity and characterizing therapeutic candidates quickly.

Key learning objectives

• Understand how to integrate immune cell screening in your drug discovery pipeline
• Learn about a new, high-throughput immune-cell analytical platform to expedite therapeutic assessment
• Discover how to link compound screening in immune cells with further functional genomic screening

Who should attend?

Anyone interested in identifying and testing drug candidates

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.